Allspring Global Investments
AVIR icon

Allspring Global Investments’s Atea Pharmaceuticals AVIR Stock Holding History

Allspring Global Investments’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,911
Closed -$7.15K – 2788
2023
Q2 		$7.15K Sell
1,911
-21,805
-92% -$81.6K ﹤0.01% 2559
2023
Q1 		$79.4K Buy
23,716
+20,421
+620% +$82.8K ﹤0.01% 2131
2022
Q4 		$15.8K Sell
3,295
-7,972
-71% -$40.3K ﹤0.01% 2637
2022
Q3 		$64K Buy
11,267
+9,286
+469% +$71.1K ﹤0.01% 2249
2022
Q2 		$14K Sell
1,981
-23,814
-92% -$163K ﹤0.01% 2546
2022
Q1 		$186K Sell
25,795
-1,179
-4% -$8.01K ﹤0.01% 2586
2021
Q4 		$241K Buy
+26,974
New +$420K ﹤0.01% 2585

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allspring Global Investments's AVIR Position: Q3 2023 in Review

Allspring Global Investments sold out of Atea Pharmaceuticals (AVIR) in Q3 2023, closing a stake of 1,911 shares — an estimated $7.15K sold.

Allspring Global Investments first reported a position in AVIR in Q4 2021 and held it in 7 quarters. The position peaked at $241K in Q4 2021. 119 funds tracked by Wall St. Rank hold AVIR as of Q3 2023.

  • Allspring Global Investments reported no remaining Atea Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Allspring Global Investments sold 1,911 Atea Pharmaceuticals shares in Q3 2023, an estimated $7.15K.
  • Allspring Global Investments first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • Allspring Global Investments's Atea Pharmaceuticals position peaked at $241K in Q4 2021.
  • 119 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2023.

Based on Allspring Global Investments's 13F filing for Q3 2023, filed 27 Oct 2023.